A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 4, 2006, Pages 458-464

  Skolnik, Jeffrey M ^a   Barrett, Jeffrey S ^a   Shi, Heng ^a   Adamson, Peter C ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Actinomycin D; Method; Pediatric; Pharmacokinetics; Validation; Vincristine

Indexed keywords

DACTINOMYCIN; VINCRISTINE;

ACCURACY; ARTICLE; ASSAY; CHILD; CHILDHOOD CANCER; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METHODOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; SOLID PHASE EXTRACTION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BLOOD SPECIMEN COLLECTION; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DACTINOMYCIN; FREEZING; HALF-LIFE; HUMANS; LINEAR MODELS; MASS SPECTROMETRY; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SPECIMEN HANDLING; VINCRISTINE;

EID: 30644474607     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0065-9     Document Type: Article

References (12)

1. Davidson A, Pritchard J (1998) Actinomycin D, hepatic toxicity and Wilms' tumour - a mystery explained? Eur J Cancer 34:1145-1147
2. Flamant F, Rodary C, Rey A, Praquin MT, Sommelet D, Quintana E, Theobald S, Brunat-Mentigny M, Otten J, Voute PA, Habrand JL, Martelli H, Barrett A, Terrier-Lacombe MJ, Oberlin O (1998) Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer 34:1050-1062
3. Frei E 3rd (1974) The clinical use of actinomycin. Cancer Chemother Rep 58:49-54
4. Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridges JM, Shanks RG (1982) The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 8:215-219
5. Rahmani R, Zhou XJ (1993) Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv 17:269-281
6. Green DM, Finklestein JZ, Norkool P, D'Angio GJ (1988) Severe hepatic toxicity after treatment with single-dose dactinomycin and vincristine: a report of the National Wilms' Tumor Study. Cancer 62:270-273
7. Green DM, Norkool P, Breslow NE, Finklestein JZ, D'Angio GJ (1990) Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules: a report from the National Wilms' Tumor Study. J Clin Oncol 8:1525-1530
8. Kanwar VS, Albuquerque ML, Ribeiro RC, Kauffman WM, Furman WL (1995) Veno-occlusive disease of the liver after chemotherapy for rhabdomyosarcoma: case report with a review of the literature. Med Pediatr Oncol 24:334-340
9. Veal GJ, Errington J, Sludden J, Griffin MJ, Price L, Parry A, Hale J, Pearson AD, Boddy AV (2003) Determination of anticancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 795:237-243
10. Bender RA, Castle MC, Margileth DA, Oliverio VT (1977) The pharmacokinetics of [3H]-vincristine in man. Clin Pharmacol Ther 22:430-435
11. Ludwig R, Weirich A, Abel U, Hofmann W, Graf N, Tournade MF (1999) Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9/GPOH. Med Pediatr Oncol 33:462-469
12. de Graaf SS, Bloemhof H, Vendrig DE, Uges DR (1995) Vincristine disposition in children with acute lymphoblastic leukemia. Med Pediatr Oncol 24:235-240